Equity indices witness a flat opening; Biocon shares up 4%

Equity benchmarks start the day on a flat note, with the Nifty holding on to 10,600-Level. The Sensex has managed  above 35,000.

The Sensex is down 72 points or 0.22% at 34933, and the Nifty down 24 points or 0.23% at 10604. The market breadth is negative as 217 shares advanced, against a decline of 289 shares, while 61 shares are unchanged.

Some cuts are visible in the PSU banking space, while the Bank Nifty is also down around a quarter of a percent. Midcaps, meanwhile, is trading flat.

Biocon’s shares were higher by 3.5 percent in the morning trade as the firm received a regulatory approval to a biosimilar Pegfilgrastim. The drug is used to treat patients with Nonmyeloid cancers.

Adani Ports, Wipro, Eicher Motors and Bharti Infratel are the top gainers, while Dr. Reddy’s Labs, SBI, and Grasim lost the most.

Get Two Days Free Trial Click Here

Sensex flat, Nifty below 10,700; rupee wipes out gains, Dr Reddy's top gainer

The market erased all its opening gains to trade lower despite strong global cues, pulled down by HDFC Bank that fell 2 percent on profit booking.

The Sensex is down around 100 points and the Nifty slips below 10,700 while the Nifty Bank index falls 200 points.

HDFC, TCS and FMCG stocks are under pressure while Reliance Industries, Infosys, ICICI Bank supported the market.

Dr Reddy's Labs is the top gainer among Nifty50 stocks, rising nearly 3% after getting zero observations for Srikakulam plant from USFDA.

Reference By- https://www.moneycontrol.com/news/business/markets/market-live-sensex-flat-nifty-below-10700-rupee-wipes-out-gains-dr-reddys-top-gainer-2581839.html

What would be result of L&T, NTPC ?

Today would be declared the result of L&T, NTPC, and Arvindo Pharma. and the results of Bank of India and Oil India will also come. Let's know how come the results of veterans?

L&T

According to Experts, In the fourth quarter of the fiscal year 2018, L&T's profits could remain flat with Rs 3,027 crore. In the fiscal year 2017, L&T's profits in the fourth quarter were Rs 3,025 crore. In the fourth quarter of the financial year 2018, L&T's earnings could increase by 12.7 percent to Rs 41,535 crore. In the fourth quarter of the fiscal year 2017, L&T's income was Rs 36,828 crore. 

Arvindo Pharma

According to Experts, In the fourth quarter of the fiscal year 2018, the profit of Arvindo Pharma could increase by 17 percent to Rs 622.65 crore. In the fourth quarter of the fiscal year 2017, the profit of Arvindo Pharma was Rs 532.2 crores. In the fourth quarter of the fiscal year 2018, the earnings of Arvindo Pharma could go increase by 17 percent to Rs 4,260 crore. In the fourth quarter of the fiscal year 2017, the income of Arvindo Pharma was Rs 3,641.6 crores.

NTPC

According to Experts, In the fourth quarter of the fiscal year 2018, NTPC's profits could increase by 28 percent to Rs 2,663 crore. NTPC's profits in the fourth quarter of the fiscal year 2017 were Rs 2,080 crore. In the fourth quarter of the fiscal year 2018, NTPC's earnings could increase by 7.5 percent to Rs 21,950 crore. In the fourth quarter of the fiscal year 2017, NTPC's income was Rs 20,417 crore.

Get 2 Days Free Trial click here